Brian Murphy, MD, MPH, MBA, MS
Chief Executive Officer, Chief Medical Officer and Director
Dr. Murphy has more than 20 years of experience in drug development and evaluation. Most recently he served as the Chief Medical Officer of Eiger Biopharmaceuticals (NASDAQ: EIGR), and prior to that held the same position at Bausch Health Companies (NYSE: BHC; formerly Valeant Pharmaceuticals International). Dr. Murphy has also served as Vice President of Sales and Marketing-Hepatology at InterMune, Inc., and Medical Director of North America (Anti-Infectives and Transplant) at Hoffmann-LaRoche, as well as Assistant Professor of Medicine at New York Medical College and Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City. He is board-certified in internal medicine, and earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business. Dr. Murphy also completed parallel fellowships in clinical epidemiology/infectious diseases and medical ethics at Harvard affiliates, Massachusetts General Hospital and Brigham and Women’s Hospital, respectively.
Doug Cesario, MBA
Chief Financial Officer
Mr. Cesario has more than 15 years of financial and operational experience, most recently as Chief Financial Officer of Kaiser Permanente Foundation Hospitals and Health Plan in the Orange County, California marketplace, where he managed the financial performance of the health system with an operating budget of over $1 billion per year. Prior financial leadership positions have included founder of Community Capital Advisory Group, a real estate advisory and investment company; director of Skye Automotive; a private equity fund; and corporate finance associate at both full service and boutique investment banking firms. Mr. Cesario earned his MBA at the UCLA Anderson School of Management.
Vice President Business Operations
Ms. Cunning has more than 20 years of experience in sales, marketing, global new product development, commercialization, and lifecycle management in the biopharmaceutical industry. Prior to Emerald Bioscience, she served as Director, New Products, U.S. Eye Care at Allergan, where she led the creation of the business unit strategy for the U.S. ocular franchise. Ms. Cunning has also served as the Associate Director of Marketing at Amylin Pharmaceuticals, leading the global life-cycle management for Byetta®. She has held multiple leadership positions at Valeant Pharmaceuticals, including the global marketing and commercial development lead for both the viral hepatitis and HIV franchises. Prior to joining Valeant, Ms. Cunning worked in Hepsera® marketing at Gilead Sciences and sales in HIV and respiratory medicine at GlaxoSmithKline. She earned a BSc in biology from West Virginia University.